David has a successful track record in leading Drug Discovery, Research and Development programs at mid sized and emerging Biotech companies which led to numerous late stage clinical development candidates and product launches.

While VP of Research and site head at Celgene, San Diego, he led the initial project team that developed Otezla. At Syrrx (now Takeda) as VP Drug Discovery, he founded and led the team that discovered and developed Nesina (alogliptin) for type II diabetes; at OSI Pharmaceuticals as Corporate VP of Discovery he was associated with thel acquisition and development of Tarceva. During his years at Syntex (now Roche) as Distinguished Scientist and Director, Institute of Immunology and Biological Science, he was part of the development team for CelCept, a drug that treats transplant rejection.

David has published more than 200 papers and abstracts and has been a member of numerous editorial boards and study sections in Immunology.  David obtained his Ph.D. in Microbiology from Rutgers University.